Paricalcitol cas 131918-61-1

Paricalcitol, marketed by Abbott Laboratories under the trade name Zemplar, is a drug used for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. It is an analog of 1,25-dihydroxyergocalciferol, the active form of vitamin D2. Paricalcitol binds to the vitamin D receptor and has been shown to reduce parathyroid hormone levels. This agent also increases the expression of PTEN ('Phosphatase and Tensin homolog deleted on chromosome Ten'), a tumor-suppressor gene, in leukemic cells and cyclin-dependent kinase inhibitors.

Related Prodcuts:

Paricalcitol CD ring intermediate; Paricalcitol Impurity 19; Paricalcitol Intermediate A; Paricalcitol Intermediate(1263504-45-5; 138079-58-0)

[1]. Martinez-Moreno JM, et al. In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/beta-catenin activation. Am J Physiol Renal Physiol. 2012 Aug 8.

[2]. Meems LM, et al. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J Steroid Biochem Mol Biol. 2012 Jul 16;132(3-5):282-289.